Dissemin is shutting down on January 1st, 2025

Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 2(57), p. 930-935, 2013

DOI: 10.1128/aac.02159-12

Links

Tools

Export citation

Search in Google Scholar

HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.

Journal article published in 2012 by Patricia Recordon-Pinson, S. Raymond, Pantxika Bellecave, Marcelin Ag, P. Marcelin, Anne-Geneviève Marcelin ORCID, Cathia Soulie, Diane Descamps, Vincent Calvez, Harrigan Pr, P. R. Harrigan, H. Fleury, Jacques Izopet, B. Masquelier, S. Ac11 Resistance Study Group
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF) on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novo selection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.